GlassScriptPhysician profile
Julie E Mariotti
NPI 1790767374
$2,393.17
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $771 · 2021: $369 · 2022: $463 · 2023: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $392.76 | 2019-2023 | Breztri, Farxiga |
| Novo Nordisk INC | $251.35 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $229.70 | 2019-2023 | |
| Abbvie INC. | $210.91 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.42 | 2019-2023 | Spiriva Respimat |
| Lilly USA, LLC | $138.97 | 2019-2023 | Jardiance, Emgality |
| Astellas Pharma US INC | $138.29 | 2019-2023 | Myrbetriq |
| Amgen INC. | $109.94 | 2019-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $108.11 | 2020 | |
| Glaxosmithkline, LLC. | $67.05 | 2022-2023 | Arexvy, Trelegy Ellipta |
| Ironshore Pharmaceuticals INC. | $64.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $63.15 | 2020-2021 | |
| Exact Sciences Corporation | $49.97 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $48.09 | 2020-2021 | |
| Allergan, INC. | $44.30 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $42.63 | 2022-2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $40.08 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $32.01 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $26.28 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $25.05 | 2023 | |
| Xeris Pharmaceuticals, INC. | $24.10 | 2020 | |
| Medtronic, INC. | $20.13 | 2022 | |
| Eisai INC. | $19.48 | 2020 | |
| Dexcom, INC. | $19.41 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.35 | 2022 | |
| Esperion Therapeutics, INC. | $14.92 | 2020 | |
| Bioventus LLC | $13.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Mariotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.